Theranostics: A Transformative Approach to Cancer Treatment

Theranostics, a branch of precision medicine, has emerged as a groundbreaking advancement in cancer treatment. At the forefront of this innovation is renowned Japanese researcher Dr. Shuichi Shiratori, who has pioneered this treatment method for over 20 years in both Japan and Thailand. Currently serving as an Associate Professor in the Department of Radiology at Siriraj Hospital, Thailand, Dr. Shiratori is an expert in radiopharmaceuticals and has made significant contributions to cancer treatment.

During his recent visit to Bangladesh as part of an initiative by Medinvest Limited, Dr. Shiratori exchanged insights with local oncologists. He was also the keynote speaker at the 4th International Medical Physics in Radiation Oncology and Imaging Conference, hosted by BRAC University. On Thursday evening, he engaged with local journalists at a hotel in Gulshan, where he discussed the transformative potential of nuclear medicine and theranostics in cancer treatment. DigiBanglaTech.News Executive Editor S. M. Imdadul Haque conducted the interview.

Question: What is theranostics?

Answer: Theranostics is an innovative approach that integrates diagnostic imaging with targeted therapy using radiopharmaceuticals. Its primary goal is to precisely target and destroy cancer cells while minimizing damage to healthy tissues. By identifying cancer biomarkers through imaging, theranostics allows for the accurate application of radiation therapy, leading to more effective treatment outcomes with fewer side effects.

Question: How has precision medicine impacted cancer treatment?

Answer: Precision medicine has revolutionized cancer treatment by tailoring therapies based on a patient’s genetic and molecular profile. This approach not only enhances treatment effectiveness but also reduces adverse side effects. A remarkable example is the use of 177Lu-PSMA in prostate cancer treatment, which has demonstrated exceptional success in targeted therapy.

Question: What challenges do you see in the implementation of precision medicine and theranostics?

Answer: Despite its immense potential, several challenges hinder the adoption of precision medicine and theranostics. These include high costs, limited infrastructure, and the need for specialized training. Regulatory barriers and quality control are also significant obstacles. However, I believe that international collaboration, particularly with organizations such as the International Atomic Energy Agency (IAEA), can help overcome these challenges.

Question: What is the future of cancer treatment?

Answer: I am optimistic about the future. I firmly believe that theranostics will be a game-changer in cancer management. However, achieving this goal requires sustained investment in research, infrastructure development, and training. International cooperation will be crucial in making these advanced treatments more accessible and affordable.

Question: How does nuclear medicine differ from conventional cancer treatments?

Answer: Traditional cancer treatments, such as surgery, radiation, and chemotherapy, often come with significant side effects and uncertain survival rates. In contrast, nuclear medicine and theranostics use targeted radiopharmaceuticals to precisely attack cancer cells while largely preserving healthy tissues. This approach not only improves treatment efficacy but also reduces side effects, enhancing patients' quality of life.

Question: How widely accepted is theranostics globally?

Answer: Theranostics is gaining global acceptance. Countries in Europe, the United States, Japan, and Australia have already incorporated it into standard cancer treatments. Thailand has also adopted this approach. Although it is difficult to quantify the exact number of patients treated with theranostics, success stories are increasing, and more countries are beginning to embrace this innovative method.

Question: What are the prospects and future of theranostics in Bangladesh?

Answer: I am confident about the potential of nuclear medicine and theranostics in transforming cancer treatment in Bangladesh. While the country has a strong healthcare infrastructure, success will depend on shifting the mindset of healthcare professionals and providing necessary training. Theranostics is becoming essential for bringing advanced treatments to Bangladesh. Through nuclear medicine, cancer patients can receive more effective, personalized, and non-invasive treatment options. With continued investment and international cooperation, Bangladesh can emerge as a leader in theranostics in the region.

Question: How affordable and accessible is this treatment for the general public?

Answer: While the initial cost of theranostics may seem high, the long-term benefits make it a cost-effective alternative. Reduced side effects and improved survival rates contribute to overall cost savings. In fact, when compared to conventional treatments, theranostics is not significantly more expensive and is becoming a viable option for patients from diverse economic backgrounds.

Question: Do you have any advice for Bangladeshi healthcare professionals?

Answer: Bangladeshi healthcare professionals should embrace nuclear medicine and theranostics. Proper training, collaboration, and a clear understanding of these advanced treatments are essential for successful implementation. With the right mindset and support, Bangladesh can become part of the global movement towards more effective and personalized cancer treatment.